mRNA COVID-19疫苗接种与荨麻疹之间的关系:丹麦一项基于全国登记的队列研究

IF 2.6 3区 医学 Q2 PUBLIC, ENVIRONMENTAL & OCCUPATIONAL HEALTH
Elena Dudukina, Elvira V Brâuner, CæcilieB Christiansen, Stine H Mogensen, Mona E Hervig, Stine Ulsø, Martin Z Larsen
{"title":"mRNA COVID-19疫苗接种与荨麻疹之间的关系:丹麦一项基于全国登记的队列研究","authors":"Elena Dudukina, Elvira V Brâuner, CæcilieB Christiansen, Stine H Mogensen, Mona E Hervig, Stine Ulsø, Martin Z Larsen","doi":"10.1177/14034948251333901","DOIUrl":null,"url":null,"abstract":"<p><strong>Objectives: </strong>To investigate the association between mRNA COVID-19 vaccination and the risk of urticaria.</p><p><strong>Study design: </strong>Nationwide observational cohort study.</p><p><strong>Setting: </strong>Healthcare registers in Denmark.</p><p><strong>Participants: </strong>The vaccinated cohort included Danish residents aged ⩾5 years who received at least one dose of Comirnaty (Pfizer-BioNTech, BNT) or Spikevax (Moderna, MOD) in December 2020 to July 2023; the pre-pandemic (2017-19) general population aged ⩾5 years formed the comparator cohort.</p><p><strong>Methods: </strong>Urticaria-free participants were followed from the vaccination date until the earliest of the incident chronic or other types of urticaria diagnosis, COVID-19 infection, end of the 90-day outcome risk window, death, emigration, or October 2023. The expected number of urticaria events was computed using indirect standardisation of the pre-pandemic urticaria incidence rates. Standardised incidence ratios (SIRs) with corresponding 95% confidence intervals (CIs) were calculated overall and across sex, age and vaccine sequence-specific strata.</p><p><strong>Results: </strong>We ascertained 4,700,301 vaccinated and 5,480,146 pre-pandemic comparators. Following all vaccine product sequences, SIRs (95% CI) were 0.83 (0.71-0.96) for chronic urticaria and 1.14 (95% CI 1.03-1.25) for other types of urticaria. Among MOD schedule adherers, the risk was three to fourfold increased for chronic (SIR 3.00, 95% CI 2.27-3.88) and other types of urticaria (SIR 3.65, 95% CI 3.06-4.31). Sensitivity analyses of dose specific effects confirmed a fourfold increased risk after MOD vaccine sequence but not BNT.</p><p><strong>Conclusions: </strong>Following the most recent mRNA vaccination dose, MOD vaccine schedule adherers had a higher than expected incidence of chronic and other types of urticaria. We found no association between BNT vaccination schedule and increased risk of urticaria.</p>","PeriodicalId":49568,"journal":{"name":"Scandinavian Journal of Public Health","volume":" ","pages":"14034948251333901"},"PeriodicalIF":2.6000,"publicationDate":"2025-05-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Associations between mRNA COVID-19 vaccination and urticaria: a nationwide registry-based cohort study in Denmark.\",\"authors\":\"Elena Dudukina, Elvira V Brâuner, CæcilieB Christiansen, Stine H Mogensen, Mona E Hervig, Stine Ulsø, Martin Z Larsen\",\"doi\":\"10.1177/14034948251333901\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><strong>Objectives: </strong>To investigate the association between mRNA COVID-19 vaccination and the risk of urticaria.</p><p><strong>Study design: </strong>Nationwide observational cohort study.</p><p><strong>Setting: </strong>Healthcare registers in Denmark.</p><p><strong>Participants: </strong>The vaccinated cohort included Danish residents aged ⩾5 years who received at least one dose of Comirnaty (Pfizer-BioNTech, BNT) or Spikevax (Moderna, MOD) in December 2020 to July 2023; the pre-pandemic (2017-19) general population aged ⩾5 years formed the comparator cohort.</p><p><strong>Methods: </strong>Urticaria-free participants were followed from the vaccination date until the earliest of the incident chronic or other types of urticaria diagnosis, COVID-19 infection, end of the 90-day outcome risk window, death, emigration, or October 2023. The expected number of urticaria events was computed using indirect standardisation of the pre-pandemic urticaria incidence rates. Standardised incidence ratios (SIRs) with corresponding 95% confidence intervals (CIs) were calculated overall and across sex, age and vaccine sequence-specific strata.</p><p><strong>Results: </strong>We ascertained 4,700,301 vaccinated and 5,480,146 pre-pandemic comparators. Following all vaccine product sequences, SIRs (95% CI) were 0.83 (0.71-0.96) for chronic urticaria and 1.14 (95% CI 1.03-1.25) for other types of urticaria. Among MOD schedule adherers, the risk was three to fourfold increased for chronic (SIR 3.00, 95% CI 2.27-3.88) and other types of urticaria (SIR 3.65, 95% CI 3.06-4.31). Sensitivity analyses of dose specific effects confirmed a fourfold increased risk after MOD vaccine sequence but not BNT.</p><p><strong>Conclusions: </strong>Following the most recent mRNA vaccination dose, MOD vaccine schedule adherers had a higher than expected incidence of chronic and other types of urticaria. We found no association between BNT vaccination schedule and increased risk of urticaria.</p>\",\"PeriodicalId\":49568,\"journal\":{\"name\":\"Scandinavian Journal of Public Health\",\"volume\":\" \",\"pages\":\"14034948251333901\"},\"PeriodicalIF\":2.6000,\"publicationDate\":\"2025-05-29\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Scandinavian Journal of Public Health\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.1177/14034948251333901\",\"RegionNum\":3,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q2\",\"JCRName\":\"PUBLIC, ENVIRONMENTAL & OCCUPATIONAL HEALTH\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Scandinavian Journal of Public Health","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1177/14034948251333901","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"PUBLIC, ENVIRONMENTAL & OCCUPATIONAL HEALTH","Score":null,"Total":0}
引用次数: 0

摘要

目的:探讨新冠肺炎疫苗接种mRNA与荨麻疹发病风险的关系。研究设计:全国观察队列研究。环境:丹麦的医疗保健登记处。参与者:接种疫苗的队列包括在2020年12月至2023年7月期间接受至少一剂Comirnaty (Pfizer-BioNTech, BNT)或Spikevax (Moderna, MOD)的小于5岁的丹麦居民;大流行前(2017-19年)年龄大于或等于5岁的一般人群形成了比较队列。方法:无荨麻疹的参与者从接种疫苗之日起进行随访,直到最早发生慢性或其他类型荨麻疹诊断、COVID-19感染、90天结局风险窗口结束、死亡、移民或2023年10月。使用大流行前荨麻疹发病率的间接标准化计算预期的荨麻疹事件数。标准化发病率(SIRs)与相应的95%置信区间(CIs)被计算在整体和跨性别、年龄和疫苗序列特异性阶层。结果:我们确定了4,700,301名接种疫苗者和5,480,146名大流行前比较者。在所有疫苗产品序列中,慢性荨麻疹的SIRs (95% CI)为0.83(0.71-0.96),其他类型荨麻疹的SIRs为1.14 (95% CI 1.03-1.25)。在MOD时间表坚持者中,慢性荨麻疹(SIR 3.00, 95% CI 2.27-3.88)和其他类型荨麻疹(SIR 3.65, 95% CI 3.06-4.31)的风险增加了三到四倍。剂量特异性效应的敏感性分析证实,接种MOD疫苗后风险增加4倍,而接种BNT疫苗后风险增加4倍。结论:在最近的mRNA疫苗接种剂量后,MOD疫苗计划依从者的慢性和其他类型荨麻疹的发病率高于预期。我们发现BNT疫苗接种计划与荨麻疹风险增加之间没有关联。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
Associations between mRNA COVID-19 vaccination and urticaria: a nationwide registry-based cohort study in Denmark.

Objectives: To investigate the association between mRNA COVID-19 vaccination and the risk of urticaria.

Study design: Nationwide observational cohort study.

Setting: Healthcare registers in Denmark.

Participants: The vaccinated cohort included Danish residents aged ⩾5 years who received at least one dose of Comirnaty (Pfizer-BioNTech, BNT) or Spikevax (Moderna, MOD) in December 2020 to July 2023; the pre-pandemic (2017-19) general population aged ⩾5 years formed the comparator cohort.

Methods: Urticaria-free participants were followed from the vaccination date until the earliest of the incident chronic or other types of urticaria diagnosis, COVID-19 infection, end of the 90-day outcome risk window, death, emigration, or October 2023. The expected number of urticaria events was computed using indirect standardisation of the pre-pandemic urticaria incidence rates. Standardised incidence ratios (SIRs) with corresponding 95% confidence intervals (CIs) were calculated overall and across sex, age and vaccine sequence-specific strata.

Results: We ascertained 4,700,301 vaccinated and 5,480,146 pre-pandemic comparators. Following all vaccine product sequences, SIRs (95% CI) were 0.83 (0.71-0.96) for chronic urticaria and 1.14 (95% CI 1.03-1.25) for other types of urticaria. Among MOD schedule adherers, the risk was three to fourfold increased for chronic (SIR 3.00, 95% CI 2.27-3.88) and other types of urticaria (SIR 3.65, 95% CI 3.06-4.31). Sensitivity analyses of dose specific effects confirmed a fourfold increased risk after MOD vaccine sequence but not BNT.

Conclusions: Following the most recent mRNA vaccination dose, MOD vaccine schedule adherers had a higher than expected incidence of chronic and other types of urticaria. We found no association between BNT vaccination schedule and increased risk of urticaria.

求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
Scandinavian Journal of Public Health
Scandinavian Journal of Public Health 医学-公共卫生、环境卫生与职业卫生
CiteScore
6.50
自引率
2.90%
发文量
135
审稿时长
4-8 weeks
期刊介绍: The Scandinavian Journal of Public Health is an international peer-reviewed journal which has a vision to: publish public health research of good quality; contribute to the conceptual and methodological development of public health; contribute to global health issues; contribute to news and overviews of public health developments and health policy developments in the Nordic countries; reflect the multidisciplinarity of public health.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信